Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Peptide patents



      
           
This page is updated frequently with new Peptide-related patent applications. Subscribe to the Peptide RSS feed to automatically get the update: related Peptide RSS feeds. RSS updates for this page: Peptide RSS RSS


Ntprobnp and ctnt based therapy guidance in heart failure

Roche Diagnostics Operations

Ntprobnp and ctnt based therapy guidance in heart failure

Method of detection of amino acid sequence and/or identification of peptides and proteins, by use of a new…

Method of detection of amino acid sequence and/or identification of peptides and proteins, by use of a new…


Date/App# patent app List of recent Peptide-related patents
08/20/15
20150233946 
 Tnt based diagnosis of paroxysmal atrial fibrillation patent thumbnailTnt based diagnosis of paroxysmal atrial fibrillation
The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac troponin, nt-probnp (n-terminal prohormone of brain natriuretic peptide), hscrp, il-6 (interleukin-6) and igfbp7 (insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts).
Roche Diagnostics Operations, Inc.


08/20/15
20150233945 
 Ntprobnp and ctnt based therapy guidance in heart failure patent thumbnailNtprobnp and ctnt based therapy guidance in heart failure
The present invention relates to a method for guiding heart failure treatment in a subject suffering from heart failure. The method is based on the determination of the amount of a bnp-type peptide and a cardiac troponin in a sample from said subject.
Roche Diagnostics Operations, Inc.


08/20/15
20150233937 
 Method of detection of amino acid sequence and/or identification of peptides and proteins, by use of a new derivatization reagent and synthesis of 5-formyl-benzene-1,3-disulphonic acid as derivatization reagent patent thumbnailMethod of detection of amino acid sequence and/or identification of peptides and proteins, by use of a new derivatization reagent and synthesis of 5-formyl-benzene-1,3-disulphonic acid as derivatization reagent
Present invention refers to a novel and improved method of derivatization and detection of amino acid sequence and/or identification of proteins, peptides by a new derivatization compound. Precisely, the method discloses a novel approach to derivatization of peptides or proteins by compounds comprising two or more sulfonyl groups and analysis of derivatized analytes in negative mode of operation of mass spectrometer.

08/20/15
20150233930 
 Methods and compositions employing secreted proteins that reflect autophagy dynamics within tumor cells patent thumbnailMethods and compositions employing secreted proteins that reflect autophagy dynamics within tumor cells
A diagnostic reagent or device for determining the autophagy levels of cancer cells comprises a ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying a biomarker selected from il-8, il-1β, dkk-3, fam-3c and/or lif, or an isoform, pro-form, modified molecular form including posttranslational modification, or unique peptide fragment or nucleic acid fragment thereof. Another reagent contains ligands to two or more of these biomarkers.
The Trustees Of The University Of Pennsylvania


08/20/15
20150233920 
 Antibody for skewing sex ratio and methods of use thereof patent thumbnailAntibody for skewing sex ratio and methods of use thereof
A purified antibody, or an antigen-binding fragment thereof, is provided that binds selectively to a protein specific to an x-chromosome of a mammalian sperm cell. The sperm cell protein comprises an amino acid sequence set forth in seq id nos: 4 and 9-16.
University Of Tennessee Research Foundation


08/20/15
20150233904 
 Detection of neurological diseases via measurement of neuromelanin in recirculating phagocytes patent thumbnailDetection of neurological diseases via measurement of neuromelanin in recirculating phagocytes
Methods for detecting or monitoring neurological or neurodegenerative diseases such as parkinson's disease via detection or measurement of central nervous system biomarkers within recirculating phagocytes after re-entry into the blood stream. The methods of the present invention may feature detecting neuromelanin in such recirculating phagocytes.
Msdx, Inc.


08/20/15
20150233903 
 Solid phase glycan and glycopeptide analysis and microfluidic chip for glycomic extraction, analysis and methods for using same patent thumbnailSolid phase glycan and glycopeptide analysis and microfluidic chip for glycomic extraction, analysis and methods for using same
Highly specific and novel solid phase methods for analyzing glycans and proteoglycans using a solid phase system are provided. The present invention also provides an integrated apparatus and methods of use which comprises a high-throughput glycan isolation and reverse-phase liquid chromatography (rplc) for on-chip glycan extraction, modification and separation.
The Johns Hopkins University


08/20/15
20150232930 
 Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell patent thumbnailUse of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
Described herein are methods for identifying nucleic acid sequences that modulate the function of a cell, the expression of a gene in a cell, or the biological activity of a target polypeptide in a cell. The methods involve the use of double stranded rna expression libraries, double stranded rna molecules, and post-transcriptional gene silencing techniques..
Alnylam Pharmaceuticals, Inc.


08/20/15
20150232904 
 Expression sequences patent thumbnailExpression sequences
An isolated nucleic acid encoding a leader, which has a specific sequence, an isolated leader peptide encoded by such nucleic acid, an expression cassette comprising such nucleic acid encoding a leader operably linked to a nucleic acid sequence encoding a poi, a recombinant yeast host cell or a vector comprising such expression cassette, a method of producing a poi in such yeast host cell, and further the use of the specific nucleic acid for the secretion of a poi from a host cell and/or to increase the secretion of a poi from a host cell.. .
Lonza Ltd


08/20/15
20150232877 
 Methods and compositions to enhance activity of cry endotoxins patent thumbnailMethods and compositions to enhance activity of cry endotoxins
Methods and compositions for enhancing the resistance of plants to plant pests are provided. Chimeric pesticidal polypeptides and nucleic acid molecules encoding the chimeric pesticidal polypeptides are provided.
Pioneer Hi-bred International, Inc.


08/20/15
20150232876 

Use of a receptor kinase having lysm motifs in order to improve the response of plants to lipochitooligosaccharides


The invention relates to improving the response of a plant to lipochitooligosaccharidic nod and myc-lco factors, by means of the expression, in the plant, of a polypeptide which has a sequence homology with the extracellular domain of the lysm-motif-containing receptor kinase lyr3 in medicago truncatula and which is capable of binding to lipochitooligosaccharides with an increased affinity.. .
Universite Paul Sabatier (toulouse Iii)


08/20/15
20150232873 

Plants having enhanced yield-related traits and making same


A method for enhancing various economically important yield-related traits in plants by modulating expression in a plant of a nucleic acid encoding a pmp (protein of interest) polypeptide. Plants having modulated expression of a nucleic acid encoding a pmp polypeptide, which plants have one or more enhanced yield-related traits compared with control plants are provided.
Basf Plant Science Company Gmbh


08/20/15
20150232867 

Heavy metal reduction in planta


There is described a mutant, non-naturally occurring or transgenic plant or plant cell comprising (a) a polynucleotide selected from the group consisting of: (i) a polynucleotide comprising, consisting or consisting essentially of a sequence having at least 71% sequence identity to seq id nos: 1, 2, 27, 28 or 29 or 51; or (ii) a polynucleotide comprising, consisting or consisting essentially of a sequence having at least 65% sequence identity to any of seq id nos: 3 to 23 or 30 to 50; or (iii) a polynucleotide encoding a ntmrp polypeptide comprising, consisting or consisting essentially of a sequence having at least 65% sequence identity to any of seq id nos. 24 to 26 or 52, and wherein the polypeptide has heavy metal transporter activity; or (b) a polynucleotide construct of at least 15 contiguous nucleotides in length that is at least 65% identical to a region of any of seq id nos: 1 to 23 or 27 to 51; or (c) a double-stranded rna comprising at least two sequences that are at least partially complementary to each other and wherein a sense strand comprises a first sequence and an antisense strand comprises a second sequence and wherein at least one of the sequences comprises at least 10 contiguous nucleotides of ntmrp rna; or (d) an expression vector comprising the polynucleotide as set forth in (i), (ii) or (iii) or the polynucleotide construct as set forth in (b)..
Philip Morris Products S.a.


08/20/15
20150232835 

Methods of constructing and screening diverse expression libraries


The present invention provides novel methods for producing nucleic acid fragment libraries that express highly diverse peptides or protein domains and, in particular, methods for producing nucleic acid fragment libraries wherein the nucleic acid fragments of the libraries are derived from two or more diverse characterized genomes.. .
Phylogica Limited


08/20/15
20150232825 

Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same


Provided are isolated polypeptides having cellulolytic enhancing activity, and polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using polypeptides..
Novozymes A/s


08/20/15
20150232817 

Polypeptides having peroxygenase activity


The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Novozymes A/s


08/20/15
20150232816 

Polypeptides having peroxygenase activity


The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Novozymes A/s


08/20/15
20150232578 

Hybrid proteins and uses thereof


There are disclosed hybrid proteins comprising at least one signal sequence; at least one dna binding domain; and at least one cell penetrating peptide (cpp) domain. In embodiments the cpp domain is a tat domain, and the dna binding domain is a hu domain.
Symvivo Corporation


08/20/15
20150232574 

Predictive marker for topoisomerase i inhibitors


The present invention generally relates to the fields of cancer therapy and cancer prevention. More particularly, the present invention generally relates to a diagnostic marker for predicting the efficacy of topoisomerase i (topo i) inhibitors in the treatment of cancers.
Boston Medical Center Corporation


08/20/15
20150232569 

Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis


The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ror1 antibodies or antigen binding fragments, ror1 binding peptides and ror1 vaccines.. .
The Regents Of The University Of California


08/20/15
20150232567 

Fc variants with increased affinity for fcyriic


The present invention relates to fc variants having increased affinity for fcγriic, methods for their generation, fc polypeptides comprising optimized fc variants, and methods for using optimized fc variants.. .
Xencor, Inc.


08/20/15
20150232566 

Carrier immunoglobulins and uses thereof


Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells, useful in methods of making it.
Amgen Inc.


08/20/15
20150232562 

Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors


The present invention relates to amino acid sequences and nanobodies that are directed against epidermal growth factor receptor 2 (her2), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.. .
Ablynx N.v.


08/20/15
20150232557 

Cd3 binding polypeptides


The present invention relates to mono-specific and multi-specific polypeptides that specifically bind or interact with cd3. These polypeptides can be, but are not limited to, antibodies, fragments thereof, scfvs, fabs, di-scfvs single domain antibodies, diabodies, dual variable domain binding proteins and polypeptides containing an antibody or antibody fragments.
Emergent Product Development Seattle Llc


08/20/15
20150232551 

Antibodies directed to il-17a/f heterologous polypeptides and therapeutic uses of thereof


The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17f designated herein as interleukin 17a/f (il-17a/f). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Genentech, Inc.


08/20/15
20150232547 

Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins


The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble fibroblast growth factor receptor 1 (fgfr1) fusion protein such as an extracellular domain of an fgfr1 polypeptide linked to an fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight.
Five Prime Therapeutics, Inc.


08/20/15
20150232540 

Analysis of ubiquitnated polypeptides


The disclosure relates to antibody reagents that specifically bind to peptides carrying a ubiquitin remnant from a digested or chemically treated biological sample. The reagents allow the technician to identify ubiquitinated polypeptides as well as the sites of ubiquitination on them.
Cell Signaling Technology, Inc.


08/20/15
20150232539 

Methods and compositions for detecting, imaging, and treating small cell lung cancer utilizing post-translationally modified residues and higher molecular weight antigenic complexes in proteins


The present invention discloses ectopically expressed isoaspartylated proteins and antigenic peptide fragments thereof as potential biomarkers for cancer such as small cell lung cancer. Also disclosed are antigen recognition agents capable of specifically recognizing and binding to isoaspartylated proteins and/or antigenic peptide fragments thereof.
University Of Southern California


08/20/15
20150232534 

Collagen hydrolysate and use thereof


The present invention relates to a collagen hydrolysate which is produced by enzymatic hydrolysis of type-b bone gelatin, wherein the collagen hydrolysate is formed from peptides of which at least 50% by weight, in particular at least 70% by weight have a molecular weight of 1,500 da to 3,500 da, and which have a mean molecular weight in the range from 4,000 da to 8,000 da, in particular in the range from 4,500 da to 6,000 da. The invention also relates to the use of this collagen hydrolysate as an active ingredient to maintain and/or improve the health of the bones, in particular to prevent and/or treat osteoporosis.
Gelita Ag


08/20/15
20150232533 

B7-h1, a novel immunoregulatory molecule


The invention provides novel polypeptides useful for co-stimulating t cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides..
Mayo Foundation For Medical Education And Research


08/20/15
20150232531 

Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof


The present invention relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence seq id no: 2 and a function-conservative variant. The invention also relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence seq id no: 1 or seq id no: 2 and a function-conservative variant for use in the treatment of a cardiovascular disease..
UniversitÉ De Lorraine


08/20/15
20150232530 

Method for expression of specific gene


Disclosed is a cell which can express a non-natural oligomeric protein, which has, introduced therein, a gene encoding an exogenous polypeptide corresponding to at least one endogenous polypeptide constituting a natural oligomeric protein, and in which the expression of the endogenous polypeptide is inhibited.. .
Mie University


08/20/15
20150232529 

High affinity tcr proteins and methods


T cell receptors (tcrs) that have higher affinity for a ligand than wild type tcrs are provided. These high affinity tcrs are formed by mutagenizing a t cell receptor protein coding sequence to generate a variegated population of mutants of the t cell receptor protein coding sequence; transforming the t cell receptor mutant coding sequence into yeast cells; inducing expression of the t cell receptor mutant coding sequence on the surface of yeast cells; and selecting those cells expressing t cell receptor mutants that have higher affinity for the peptide/mhc ligand than the wild type t cell receptor protein.
The Board Of Trustees Of The University Of Illinois


08/20/15
20150232527 

Glucagon-like peptide-1 analogue monomer and dimer, preparation method therefor and application thereof


Provided are a glucagon-like peptide-1 (glp-1) analogue monomer and dimmer, a preparation method thereof, and an application thereof. The glp-1 analogue monomer comprises one cysteine; and the dimer is formed by two monomer molecules connected via an intermolecular disulfide bond formed by the cysteine.
Tianjin Institute Of Pharmaceutical Research


08/20/15
20150232526 

Use of relaxin to treat atrial fibrillation


Disclosed herein are methods of using relaxin polypeptides and analogs, or nucleic acid molecules encoding such polypeptides to treat or inhibit atrial fibrillation.. .
University Of Pittsburgh-of The Commonwealth System Of Higher Education


08/20/15
20150232523 

Use of pedf-derived polypeptides for preventing and/or ameliorating skin aging


A method for preventing and/or ameliorating skin aging in a subject includes administering to the subject in need of such treatments a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of seq id no: 1..
Mackay Memorial Hospital


08/20/15
20150232521 

Peptides and methods for inducing cell death


The invention provide isolated peptides, protides and conjugates having novel peptide sequences which are able to induce antimicrobial, anti-cancer, anti-inflammatory, anti-proliferative or programmed cell death activity. The invention also provides a method of inducing programmed cell death in a cell by contacting the cell with an isolated peptide, protide or conjugate described herein.
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center


08/20/15
20150232517 

Mutant fragments of ospa and methods and uses relating thereto


The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein a (ospa), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a borrelia infection and a method of immunizing a subject.. .
Valneva Austria Gmbh


08/20/15
20150232514 

Tfpi inhibitors and methods of use


The invention provides peptides that bind tissue factor pathway inhibitor (tfpi), including tfpi-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a tfpi, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify tfpi, and identify a tfpi-binding compound..
Baxter Healthcare Sa


08/20/15
20150232512 

Synthetic peptide for adjusting balance between presence of type 1 tnf receptor and type 2 tnf receptor and use thereof


Provided is a method for adjusting the balance of tnf-r1 and tnf-r2 in cells present at a target organ, tissue or site. In the adjustment method provided, when increasing the relative presence of tnf-r2 compared to the presence of tnf-r1 in the cells, a synthetic peptide is supplied to the cells, with the peptide being essentially made of at a tnf-r1 signal peptide motif or a modified amino acid sequence thereof; and when decreasing the relative presence of tnf-r2 compared to the presence of tnf-r1 in the cells, a synthetic peptide is supplied to the cells, with the peptide being essentially made of a tnf-r2 signal peptide motif or a modified amino acid sequence thereof..
Toagosei Co., Ltd.


08/20/15
20150232511 

Method for producing a composition for treating a tooth lesion


The invention relates to a method for preparing a composition for treating a tooth lesion, said composition comprising peptides that are capable of undergoing self-assembly at a certain ph. The compositions of the invention are highly suitable for being used in the medical field, in particular for remineralising a tooth lesion such as a subsurface caries lesion..
Credentis Ag


08/20/15
20150232510 

Dipeptidyl peptidase-iv inhibitor


An excellent peptidyl peptidase-iv inhibitor and the like are provided. A peptide consisting of val-pro-x wherein x represents an amino acid residue (except for l-proline residue); the aforementioned x is preferably one selected from a basic amino acid residue, an aliphatic neutral amino acid residue, an amide group-carrying neutral amino acid residue, or an aromatic group-carrying neutral amino acid residue; the aforementioned x is preferably one selected from an alanine residue, a glutamine residue, a methionine residue, an asparagine residue, a glycine residue, a valine residue, a tyrosine residue, a serine residue, and a lysine residue; a dipeptidyl peptidase-iv inhibitor, a blood sugar rise suppressing agent, a vascular endothelial disorder suppressing agent, and an angiotensin converting enzyme inhibitor containing the aforementioned peptide as an active ingredient..
Morinaga Milk Industry Co., Ltd


08/20/15
20150232507 

Split inteins and uses thereof


The present invention relates generally to robust split inteins. The split inteins described herein are active over a large temperature range, including temperatures as low as 0° c., over a wide ph range, and in the presence of chaotropic salts.
Era Biotech, S.a.


08/20/15
20150232503 

Method for preparing exenatide


Disclosed in the present invention is a method for preparing exenatide. Serine resin is obtained through a first coupling of serine and resin and successively with amino acids through a second coupling to obtain a peptide resin with a sequence as shown by seq id no.
Hybio Pharmaceutical Co., Ltd.


08/20/15
20150232441 

Most effective process for base-free preparation of ketone intermediates usable for manufacture of nebivolol


Comprising the steps of: activation of a carboxylic acid by using a peptide coupling agent, coupling of the activated carboxylic acid with a malonic acid derivative providing a β-ketoester precursor and converting the β-ketoester precursor to the ketone of the general formula 1.. .

08/20/15
20150231285 

Radiolabeled active targeting pharmaceutical composition and the use thereof


The present invention is related to a radiolabeled active targeting pharmaceutical composition, including: a bioconjugate and a radionuclide, wherein the bioconjugate includes a biomolecule and a metal nanoparticle, wherein the biomolecule has an affinity for receptors on the surface of a cell membrane and is selected from the group consisting of a peptide and a protein. The present invention further provides a method for evaluating a thermal adjuvant therapy for tumors and a kit thereof.
National Yang-ming University


08/20/15
20150231274 

Dextran-peptide hybrid for efficient gene delivery


One or more embodiments of the present invention provide a novel composition for gene delivery are directed to a group of polysaccharide polymers, having one or more nucleic acid delivery side chains comprising cationic peptides. In some embodiments, these cationic peptides condense and physically bond to one or more nucleic acids to form a polysaccharide-nucleic acid complex that permits delivery to and transfection of the nucleic acid(s) into cells.
The University Of Akron


08/20/15
20150231253 

Systems and methods for delivery of peptides


The present invention generally relates to compositions and methods for topical or transdermal delivery. The compositions can be used in a variety of applications.
Transdermal Biotechnology, Inc.


08/20/15
20150231252 

Peptide metabolic conditions


The present invention generally relates to compositions and methods for topical or transdermal delivery, and treatment of metabolic conditions. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (trh) and/or gnrh (gonadotropin-releasing hormone).
Transdermal Biotechnology, Inc.


08/20/15
20150231239 

Compositions and methods for rendering tumor cells susceptible to cd8+ t cell-mediated killing


The present invention provides an immunoconjugate having the formula: t-c-en-c-fcn or t-c-fcn-c-en; wherein, t is a single chain variable portion fragment of a monoclonal antibody (scfv) directed to a target protein, polypeptide, or fragment thereof, which is highly expressed on cancer cells; e is two or more foreign immunogenic cd8+ t cell antigenic epitopes; c is a peptide or polypeptide fragment thereof, capable of being cleaved by a specific protease; and fc is two or more fc portions of an igg antibody. Nucleic acid sequences encoding the same and vectors containing said nucleic acid sequences are also provided.
The Johns Hopkins University


08/20/15
20150231222 

Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides


The present invention provides peptides having an amino acid sequence as set forth in seq id no: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic t cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of mphosph1 and/or depdc1, e.g.
Oncotherapy Science, Inc.


08/20/15
20150231218 

Methods and materials for generating cd8+ t cells having the ability to recognize cancer cells expressing a her2/neu polypeptide


This document provides methods and materials for generating cd8+ t cells having the ability to recognize cancer cells expressing a her2/neu polypeptide. For example, methods and materials for using a polypeptide consisting of an slaflpesfd amino acid sequence in vivo or in vitro to generate cd8+ t cells having the ability to recognize and lyse cancer cells expressing a her2/neu polypeptide are provided..
Mayo Foundation For Medical Education And Research


08/20/15
20150231217 

Composition and methods for treating melanoma


The present invention encompasses novel peptides useful for preventing and treating cancer, particularly melanoma. Multiple sequences of interest are provided and these sequences have been incorporated into other peptides to obtain a series of peptides of about 30 amino acid residues in length wherein the properties of each combine to yield an effective cocktail for treating melanoma, which surpasses the use of single peptides as immunogens, as well as shorter peptides as immunogens..
University Of Virginia Patent Foundation


08/20/15
20150231216 

Compound comprising an autoantigenic peptide and a carrier with a mhc binding motif


The invention relates a compound comprising (a) a peptide and (b) a carrier, wherein said peptide having at least the motif x-x-x-x-x-x-x, wherein at least one amino acid residue x is glycosylated, said peptide being linked to the peptide binding protein and said carrier comprises at least a mhc binding motif being linked to said peptide as well as pharmaceutical compositions comprising said compound and the use of said compound or pharmaceutical composition for the treatment of a disease, such as an inflammatory joint disease. The subject matter of the application is exemplified with peptides derived from type ii collagen such as peptides having at least the sequence agfkgea, or iagfkgeqpkg, or the peptide aaakaaa.
Vacara Ab


08/20/15
20150231215 

Vista antagonist and methods of use


The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of vista. The invention further contemplates therapeutic use of the vista antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist..

08/20/15
20150231210 

Pharmaceutical composition for treating a metabolic syndrome


The invention is directed to a pharmaceutical composition containing at least one fgf-21 (fibroblast growth factor 21) compound, at least one glp-1r (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one dpp-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.. .
Sanofi


08/20/15
20150231208 

Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain


The present invention relates to use of cometin in a method of treatment of allodynia, hyperalgesia, spontaneous pain and/or phantom pain. In a preferred embodiment the disorder to be treated is thermal allodynia and thermal hyperalgesia.
Nsgene A/s


08/20/15
20150231206 

Variant activin receptor polypeptides and uses thereof


The present invention provides variant activin iib soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin a, myostatin, or gdf-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins.
Amgen Inc.


08/20/15
20150231205 

Compositions and methods for the treatment of myocardial ischemia/reperfusion injury with annexin a1 short peptide


The present invention provides a method of treating, ameliorating or preventing myocardial ischemia/reperfusion injury in a subject in need thereof, by administering to the subject a therapeutically effective amount of an anxa1short peptide (anxa1sp).. .
Duke University


08/20/15
20150231204 

Pancreatic polypeptide family motifs, polypeptides and methods comprising the same


The present invention provides novel pancreatic polypeptide family (“ppf”) polypeptides and methods for their use.. .
Astrazeneca Pharmaceuticals Lp


08/20/15
20150231202 

High affinity ny-eso t cell receptors


The present invention provides t cell receptors (tcrs) having the property of binding to sllmwitqc-hla-a*0201, the sllmwitqc seq no:126 peptide being derived from the ny-eso-1 protein which is expressed by a range of tumour cells. The tcrs have a kd for the said peptide-hla complex of less than or equal to 1 μm and/or have an off-rate (koff) of 1×10−3 s−1 or slower..
Adaptimmune Limited


08/20/15
20150231199 

Peptides and their uses


Disclosed are antimicrobial peptides. Also disclosed are methods of treating bacterial infection and fungal infection and a method of removing biofilm.
Singapore Health Services Pte Ltd


08/20/15
20150231195 

Competitive inhibitors of invariant chain expression and/or ectopic clip binding


The invention relates to methods for modulating the immune function through targeting of clip molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, alzheimer's disease, allergic disease, transplant and cell graft rejection, hiv infection and other viral, bacterial, and parasitic infection, and aids.
Regents Of The University Of Colorado, A Body Corporate


08/20/15
20150231194 

Biotechnological production of cyanophycin dipeptides


The present invention relates to a process for the enzymatic production of a dipeptide composition from a cyanophycin (cgp) or cgp-like polymer preparation by degrading the polymer preparation with an cgpase, a cgpase particularly adapted for said process, and the use of cyanophycin (cgp) or cgp-like polymers or fragments thereof, notably a dipeptide composition obtained by the process as defined above, as pharmaceutical composition, medicament, or as food or feed substitute.. .
WestfÄlische Wilhelms-universitÄt MÜnster


08/20/15
20150231171 

Nylon-3 co-polymers and synthetic lung surfactant compositions containing same


Non-natural oligomers have recently shown promise as functional analogues of lung surfactant proteins b and c (sp-b and sp-c), two helical and amphiphilic proteins that are critical for normal respiration. The generation of non-natural mimics of sp-b and sp-c has previously been restricted to step-by-step, sequence-specific synthesis, which results in discrete oligomers that are intended to manifest specific structural attributes.
Wisconsin Alumni Research Foundation


08/20/15
20150231168 

Methods for sustained and regulatable gene expression using viral based expression vectors


Disclosed are genetic expression cassettes, and vectors comprising them useful for the delivery of isolated nucleic acid segments including those expressing or encoding one or more selected therapeutic constructs (including, without limitation, therapeutic peptides, polypeptides, ribozymes, or catalytic rna molecules), to one or more selected cells or tissues of a vertebrate animal. Methods employing the disclosed genetic constructs in the development of gene therapy-based viral vector systems are also disclosed.
University Of Florida Research Foundation, Inc.


08/20/15
20150231053 

Treatment of skin, including aging skin, to improve appearance


The present invention generally relates to compositions and methods for topical or transdermal delivery, treatment of skin, and improving the appearance of skin, e.g., medically or cosmetically. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (trh) and/or gnrh (gonadotropin-releasing hormone).
Transdermal Biotechnology, Inc.




Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Peptide for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Peptide with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.2462

5136

1 - 1 - 114